ELIZABETH HILL to Multiple Myeloma
This is a "connection" page, showing publications ELIZABETH HILL has written about Multiple Myeloma.
Connection Strength
0.587
-
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2021 Nov 01; 7(11):1678-1685.
Score: 0.150
-
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist. 2021 04; 26(4):288-e541.
Score: 0.144
-
Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 2019 02 04; 9(2):15.
Score: 0.124
-
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):1781-1783.
Score: 0.123
-
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024 Oct 01; 30(19):4482-4490.
Score: 0.046